Back to Search
Start Over
Transient gain of function of cannabinoid CB 1 receptors in the control of frontocortical glucose consumption in a rat model of Type-1 diabetes.
- Source :
-
Brain research bulletin [Brain Res Bull] 2020 Aug; Vol. 161, pp. 106-115. Date of Electronic Publication: 2020 May 16. - Publication Year :
- 2020
-
Abstract
- Here we aimed to unify some previous controversial reports on changes in both cannabinoid CB <subscript>1</subscript> receptor (CB <subscript>1</subscript> R) expression and glucose metabolism in the forebrain of rodent models of diabetes. We determined how glucose metabolism and its modulation by CB <subscript>1</subscript> R ligands evolve in the frontal cortex of young adult male Wistar rats, in the first 8 weeks of streptozotocin-induced type-1 diabetes (T1D). We report that frontocortical CB <subscript>1</subscript> R protein density was biphasically altered in the first month of T1D, which was accompanied with a reduction of resting glucose uptake ex vivo in acute frontocortical slices that was normalized after eight weeks in T1D. This early reduction of glucose uptake in slices was also restored by ex vivo treatment with both the non-selective CB <subscript>1</subscript> R agonists, WIN55212-2 (500 nM) and the CB <subscript>1</subscript> R-selective agonist, ACEA (3 μM) while it was exacerbated by the CB <subscript>1</subscript> R-selective antagonist, O-2050 (500 nM). These results suggest a gain-of-function for the cerebrocortical CB <subscript>1</subscript> Rs in the control of glucose uptake in diabetes. Although insulin and IGF-1 receptor protein densities remained unaffected, phosphorylated GSKα and GSKβ levels showed different profiles 2 and 8 weeks after T1D induction in the frontal cortex. Altogether, the biphasic response in frontocortical CB <subscript>1</subscript> R density within a month after T1D induction resolves previous controversial reports on forebrain CB <subscript>1</subscript> R levels in T1D rodent models. Furthermore, this study also hints that cannabinoids may be useful to alleviate impaired glucoregulation in the diabetic cortex.<br />Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest. The funding agencies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Subjects :
- Analgesics pharmacology
Animals
Benzoxazines pharmacology
Diabetes Mellitus, Experimental genetics
Diabetes Mellitus, Type 1 genetics
Disease Models, Animal
Frontal Lobe drug effects
Male
Morpholines pharmacology
Naphthalenes pharmacology
Organ Culture Techniques
Rats
Rats, Wistar
Receptor, Cannabinoid, CB1 agonists
Receptor, Cannabinoid, CB1 antagonists & inhibitors
Receptor, Cannabinoid, CB1 genetics
Diabetes Mellitus, Experimental metabolism
Diabetes Mellitus, Type 1 metabolism
Frontal Lobe metabolism
Glucose metabolism
Receptor, Cannabinoid, CB1 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2747
- Volume :
- 161
- Database :
- MEDLINE
- Journal :
- Brain research bulletin
- Publication Type :
- Academic Journal
- Accession number :
- 32428627
- Full Text :
- https://doi.org/10.1016/j.brainresbull.2020.05.004